相关实验视频
Updated: Sep 19, 2025
05:25
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
863
针对心力衰竭的BCAA代谢向治疗,使用保存的喷射分数
Meng Wang1, Zhao Liu1, Shuxun Ren1
1Signature Research Programme in Cardiovascular and Metabolic Disorders, DukeNUS Medical School, Singapore.
Theranostics
|June 16, 2025
概括
支链氨基酸 (BCAA) 代谢受损导致心力衰竭,其中保留喷射分数 (HFpEF). 恢复 BCAA 代谢流可能为 HFpEF 患者提供新的治疗策略.
科学领域:
- 心血管医学 心血管医学
- 代谢障碍 代谢障碍 代谢障碍
- 生物化学 生化学
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭是一个重要的未满足的医疗需求.
- 代谢功能障碍,特别是在葡萄糖和脂肪酸代谢中,与HFpEF病原发生有关.
- 其他代谢途径,如分支链氨基酸 (BCAA) 代谢在HFpEF中的作用仍未得到充分研究.
研究的目的:
- 研究BCAA代谢在HFpEF中的作用.
- 探索是否增强BCAA的代谢流可以作为HFpEF的治疗策略.
主要方法:
- 基于系统的代谢学和向质谱学用于人类HFpEF患者样本.
- 使用高脂肪饮食 (HFD) 和L-NAME.建立了一个临床前HFpEF小鼠模型.
- BCAA的代谢活性是由BCKDK (分支链酸脱酶激酶) 的遗传失活化或药理抑制调节的.
主要成果:
- 在HFpEF患者和小鼠模型中观察到异常的循环BCAA水平和心脏BCAA代谢功能受损.
- 在小鼠中,BCKDK的失活改善了心脏功能,减少了心脏缩和重塑,并增强了心肌胰岛素信号传递.
- 在小鼠中,药理抑制BCKDK逆转了与HFpEF相关的透缩功能障碍和心脏缩.
结论:
- 全球 BCAA 的代谢性损伤是 HFpEF 中的一个关键的致病因子和代谢特征.
- 恢复 BCAA 代谢流是 HFpEF 的潜在治疗策略.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.6K
10:05Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.4K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
01:22Heart Failure Drugs: β-Blockers
446
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
446
01:22Heart Failure VI: Adjunct Therapies
39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:29Cardiomyopathy V: Interprofessional Care
41
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
41
01:30Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30